TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
BVX-0922 to target colorectal cancer under investigator-sponsored IND
The company showcased three core programs developed through this platform
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Nous-209 has been developed using the Nouscom's viral vector platform
Subscribe To Our Newsletter & Stay Updated
